Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA1H | O95180 | 8/20 | 0.41 |
| ▸ | WNT3A | P56704 | 4/20 | 0.41 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.40 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.40 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.40 |
| ▸ | TMIGD3 | P0DMS9 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | ABL1 | P00519 | 1/20 | 0.39 |
| ▸ | GSK3A | P49840 | 1/20 | 0.39 |
| ▸ | GSK3B | P49841 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13067793 | 0.92 | CACNA1H (0.42) | CACNA1HWNT3AKCNQ2CACNA1GCACNA1I | |
| SCHEMBL12839010 | 0.92 | WNT3A (0.42) | CACNA1HWNT3AKCNQ2CACNA1GCACNA1I | |
| SCHEMBL12839106 | 0.91 | CACNA1H (0.41) | CACNA1HWNT3ACACNA1GCACNA1IMEN1 | |
| SCHEMBL12838994 | 0.91 | TMIGD3 (0.42) | CACNA1HWNT3AKCNQ2CACNA1GCACNA1I | |
| SCHEMBL12839071 | 0.90 | CACNA1H (0.40) | CACNA1HWNT3ACACNA1GCACNA1IMEN1 | |
| SCHEMBL12840364 | 0.89 | KMT2A (0.45) | WNT3ATMIGD3MEN1KMT2ARAB9A | |
| SCHEMBL12839632 | 0.89 | KMT2A (0.52) | WNT3AMEN1KMT2ARAB9ANPC1 | |
| SCHEMBL12839947 | 0.88 | RIOK2 (0.49) | WNT3AMEN1KMT2AGSK3A | |
| SCHEMBL12839927 | 0.88 | TMIGD3 (0.43) | CACNA1HWNT3AKCNQ2CACNA1GCACNA1I | |
| SCHEMBL12840376 | 0.87 | KMT2A (0.46) | WNT3ATMIGD3MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110070656-A1 | Fluorescent Proteins | JNC CORPORATION (JP) | 2011-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070656-A1 | Fluorescent Proteins | CACYBP, CHLSN, LCP2 | CACNA1H 110/4885WNT3A 510/4885KCNQ2 1883/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.